BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, May 14, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 27, 2020
View Archived Issues
IND clearance paves way for phase II study of BXCL-501 for agitation associated with delirium
Read More
Phase II study of SHR-0302 in atopic dermatitis meets primary and secondary endpoints
Read More
Crinetics presents phase II data from ACROBAT Edge and ACROBAT Evolve studies of paltusotine
Read More
ADXS-503 shows pronounced and sustained tumor control in ongoing phase I/II study in NSCLC
Read More
CohBar presents promising preclinical data for its antifibrotic CB5138 analogue peptides
Read More
Olema and Novartis to evaluate OP-1250 in combination therapies
Read More
NOI initiates phase IIb/IIIa trial of first oral systemic NO-based therapeutic for COVID-19
Read More
Shanghai Ringene Biopharma describes new STAT3 inhibitors
Read More
ENA 2020: Progress in cancer research can come one mouse at a time, study suggests
Read More
Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical patent anti-claudin 18.2 antibodies
Read More
First cohort successfully completed in phase I study of HFB-30132A
Read More
New SGLT-1 inhibitors identified at Medshine Discovery
Read More
Shanghai Synergy Pharmaceutical Sciences, Zhejiang Huahai Pharmaceutical present BRD4 inhibitors
Read More
Prenatal treatment normalizes brain development in Down syndrome model
Read More
Dual HDAC6/VEGFR-2 inhibitors presented by Beijing Guohong Biomedical Technology
Read More
Positive interim phase II data presented for olutasidenib in AML
Read More
BioInvent receives CTA approval for first-in-human study of BI-1808 in Denmark
Read More
Ascentage cleared to begin phase Ib/II study of APG-115 for liposarcoma in China
Read More
ViralClear halts phase II study of merimepodib in hospitalized patients with COVID-19
Read More
Preclinical and clinical data presented for taminadenant + spartalizumab in cancer
Read More
GABPB1-AS1 is correlated with poor prognosis in HPV16-positive cervical cancer
Read More
APJ-specific PET radiotracer predictive of post-ischemic angiogenesis
Read More
Novel SARS-CoV-2 subunit vaccine in preclinical development
Read More
Interim data reported from phase I/II study of GTX-102 for Angelman syndrome
Read More
FDA approves IND for phase II study of VSJ-110 for allergic conjunctivitis
Read More